# The Effect of Gemcabene on Insulin Sensitivity in Nondiabetic Subjects

> **NCT02586168** · PHASE2 · COMPLETED · sponsor: **NeuroBo Pharmaceuticals Inc.** · enrollment: 53 (actual)

## Conditions studied

- Insulin Sensitivity

## Interventions

- **DRUG:** Gemcabene 900 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02586168
- **Lead sponsor:** NeuroBo Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-07
- **Primary completion:** 2001-10
- **Final completion:** 2001-10
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2020-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02586168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02586168, "The Effect of Gemcabene on Insulin Sensitivity in Nondiabetic Subjects". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02586168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*